
Annual report 2024
added 01-03-2026
BioLineRx Ltd. Net Debt 2011-2026 | BLRX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt BioLineRx Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -13.9 M | 704 K | 5.33 M | -4.86 M | -2.13 M | -5.11 M | -5.78 M | -8.87 M | -18.3 M | -8.58 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.33 M | -18.3 M | -6.14 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Adagene
ADAG
|
-71 M | $ 1.6 | 0.63 % | $ 90.1 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.43 | -2.56 % | $ 8.25 B | ||
|
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.41 | -6.0 % | $ 360 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
-115 M | $ 67.35 | 2.15 % | $ 9.01 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Biogen
BIIB
|
4.01 B | $ 181.5 | -2.22 % | $ 26.4 B | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Bristol-Myers Squibb Company
BMY
|
37.4 B | $ 56.21 | 0.79 % | $ 114 B | ||
|
AstraZeneca PLC
AZN
|
9.86 B | $ 93.61 | -0.03 % | $ 96.9 B | ||
|
BeiGene, Ltd.
BGNE
|
-2.44 B | - | 0.49 % | $ 251 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 4.22 | -0.71 % | $ 9.18 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | ||
|
Catalyst Biosciences
CBIO
|
-33.1 M | $ 11.09 | 1.0 % | $ 730 M | ||
|
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 215.99 | 3.46 % | $ 5 B | ||
|
Codiak BioSciences
CDAK
|
-39.4 M | - | -55.98 % | $ 2.15 M | ||
|
Coherus BioSciences
CHRS
|
-101 M | $ 1.7 | 3.03 % | $ 160 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Cerevel Therapeutics Holdings
CERE
|
-33.6 M | - | - | $ 7.29 B | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Celldex Therapeutics
CLDX
|
-24.5 M | $ 26.46 | 3.08 % | $ 1.7 M | ||
|
Cellectis S.A.
CLLS
|
-206 M | $ 4.21 | -1.29 % | $ 116 M | ||
|
Caladrius Biosciences
CLBS
|
-22.3 M | - | -16.75 % | $ 25.8 M | ||
|
Clearside Biomedical
CLSD
|
-27.9 M | - | - | $ 25.3 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
-121 M | - | - | $ 3.77 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
-514 M | $ 22.14 | -4.67 % | $ 2.62 B | ||
|
Chimerix
CMRX
|
-25.8 M | - | - | $ 756 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-213 M | $ 54.96 | -0.71 % | $ 4.44 B | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 107.43 | 5.14 % | $ 27.2 B | ||
|
CRISPR Therapeutics AG
CRSP
|
-74.6 M | $ 55.66 | 0.65 % | $ 4.7 B | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 28.93 | -1.6 % | $ 1.4 B | ||
|
CTI BioPharma Corp.
CTIC
|
18.3 M | - | - | $ 1.2 B |